They showed that PPI network and enrichment analyzes identified useful drug targets to prevent the onset of severe COVID-19 including key antiviral pathways such as Toll-like receptor cascades, NOD-like receptor signaling, interferon RIG induction ( IFN) α/β, and interleukin (IL)-1, IL-6, IL-12, IL-18, and tumor necrosis factor and also innate immune evasion of SARS-CoV-2 and involvement of MYD88 and MAVS in the pathophysiology of COVID-19. This evidence concerns the gene MAVS and COVID-19.